Delivery Order SPE2DB22D2108-SPE2DB25FU5PS
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Mounjaro (tirzepatide) 10 mg/0.5 mL pens valued at $13,934.62 on May 6, 2025, with completion scheduled for May 7, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion pharmaceutical supply vehicle running through...
- The Defense Logistics Agency awarded a $11,495.12 delivery order to AmerisourceBergen Drug Corp for Mounjaro (tirzepatide) 5 mg/0.5 mL pens on May 27, 2025, with completion scheduled for May 28, 2025. This competitively awarded, firm fixed-price contract requires delivery to the company's facility in Conshohocken, Pennsylvania. The award represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and...
- The Defense Logistics Agency awarded a $1,066.53 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Mounjaro (tirzepatide) 12.5 mg/0.5 mL pen injectors, with performance in Conshohocken, Pennsylvania and completion by September 25, 2025. This competitive award carries no set-aside designation and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply contract vehicle with DLA. AmerisourceBergen Drug Corp, a major pharmaceutical distributor...
- The Defense Logistics Agency awarded a $9,733.61 firm fixed-price delivery order to AmerisourceBergen Drug Corp on June 26, 2025, for the supply of Mounjaro (tirzepatide) 5 mg/0.5 ml pens. The contract is non-competitive with no set-aside designation and carries an ultimate completion date of June 27, 2025. AmerisourceBergen will fulfill this delivery order from its corporate office location in Conshohocken, Pennsylvania, serving the federal government's pharmaceutical supply requirements....
- The Defense Logistics Agency awarded a $3,771.95 delivery order to AmerisourceBergen Drug Corp for Mounjaro (tirzepatide) 15 mg/0.5 mL pens on June 3, 2025, with completion expected by June 4, 2025. This non-set-aside contract utilizes firm fixed pricing and is fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and...
- The Defense Logistics Agency awarded a $3,109.35 delivery order to AmerisourceBergen Drug Corp on May 27, 2025, for the supply of Mounjaro (tirzepatide) 7.5 mg/0.5 ml pen injections. This is a firm fixed price, non-set-aside contract with an ultimate completion date of May 28, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $1,904.63 to AmerisourceBergen Drug Corp for Mounjaro (tirzepatide) 15 mg/0.5 ml pens on July 22, 2025, with completion scheduled for July 23, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Mounjaro is a GLP-1 receptor agonist used for diabetes management, representing part of...
- The Defense Logistics Agency awarded a $9,965.87 firm fixed price delivery order to AmerisourceBergen Drug Corp for Mounjaro (tirzepatide) 7.5 mg/0.5 mL pens on July 18, 2025, with a completion date of July 21, 2025. This non-set-aside delivery order will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. The award represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $1 billion...
- The Defense Logistics Agency awarded a delivery order valued at $11,125.48 to AmerisourceBergen Drug Corp for Mounjaro 5 mg/0.5 mL pens (tirzepatide injection), a diabetes medication, with completion targeted for September 15, 2025. This competitive, firm fixed-price delivery order represents a non-set-aside award to the pharmaceutical distributor's corporate office location in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order valued at $1,170.98 to AmerisourceBergen Drug Corp for the supply of Mounjaro (tirzepatide) 12.5 mg/0.5 mL pen injections on August 29, 2025, with completion scheduled for September 2, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through the federal procurement process. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the...
- SPE2DB22D2108Indefinite Delivery Contract
- SPE2DB22D2108-SPE2DB25FU5PSDelivery Order
The Defense Logistics Agency awarded a $1,197.56 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Mounjaro (tirzepatide) 10 mg/0.5 mL pens on August 25, 2025, with an ultimate completion date of August 26, 2025. This non-set-aside competitive award represents a pharmaceutical supply delivery executed through AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999 and extends through December 2026. The product will be delivered to AmerisourceBergen's distribution center in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. AmerisourceBergen Drug Corp serves as a critical vendor within the federal medical supply chain, supplying a comprehensive portfolio of pharmaceuticals and medical devices to support military and veteran healthcare systems. This delivery order for Mounjaro, a diabetes and weight management medication, exemplifies the company's role in providing specialty pharmaceutical products under the DLA's global pharmaceutical support program. The underlying IDC vehicle enables flexible procurement of medications and medical supplies across multiple therapeutic domains to support Department of Defense healthcare operations and other federal healthcare systems worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 8/25/25 |